Keeping Track: Jardiance Approved Across Heart Failure Spectrum, But US FDA Turns Down Bardoxolone, Terlipressin
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
You may also be interested in...
Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition
BI’s global head of innovation Michel Pairet tells In Vivo that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition
Boehringer Ingelheim's head of innovation Michel Pairet tells Scrip that while unmet medical need is the pharma’s R&D priority, its main focus is bringing breakthrough therapy potential to patients, and it is taking aim at competitive spaces like metabolic health and cancer.
Lexicon’s Sotagliflozin Succeeds In Heart Failure Following Disappointment In Diabetes
Lexicon gets broad indication across heart failure for its dual SGLT1/2 inhibitor, which will be positioned against Lilly/BI’s Jardiance and AstraZeneca’s Farxiga.